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Abstract 
Macrophage Migration Inhibitory Factor (MIF) was one of the first cytokines to be 
discovered over 50 years ago and has been characterised in a wide range of 
mammalian and parasite species. This unique protein possesses the characteristics of a 
cytokine, chemokine and hormone along with two distinct enzymatic activities. MIF 
has been shown to be involved in innate and adaptive immunity by modulating Toll-
like receptor 4 (TLR4) intermediates such as MAPK and downstream pathways in 
inflammation and in cell growth and differentiation, thus playing a key role in chronic 
inflammation and tumorigenesis.  In this study, the role of parasitic and mammalian 
MIF in TLR4 signalling was investigated. Mus musculus MIF1 (MmMIF1) cDNA was 
isolated by gene cloning and recombinant fusion MmMIF1 was purified alongside 
Trichinella spiralis MIF1 (TsMIF1) by affinity and ion exchange chromatography. The 
effects of MIF on TLR4 signalling were examined by analysing the downstream 
activation of NFκB and AP-1 via a transcriptional reporter using HEK-Blue™-hTLR4 cells 
as a model. It was found that upon co-administration of TsMIF1 with LPS, NFκB 
activation was significantly reduced when compared to LPS treatment alone while 
MmMIF1 caused no significant changes in the activation levels of TLR4. Since no 
changes were observed in the NFκB and AP-1 activation levels upon co-administration 
of MIF in the Tumour necrosis factor receptor 1 (TNFR1) pathway, this downstream 
effect of TsMIF1 can be said to occur within the TLR4 cascade upstream of 
Transforming growth factor beta-activated kinase 1 (TAK1). 
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1.0 Introduction 
1.1 Innate Immunity and Pathogen Recognition 
The human body is constantly exposed to the external environment in the form of air, 
water and food that facilitate the entry of harmful factors such as hazardous 
chemicals, toxins, radiation and pathogenic microorganisms. The skin and the mucosal 
tissues of the respiratory tract, gastrointestinal (GI) tract and urogenital tract are often 
the point of entry for most pathogens. In addition, these surfaces are also occupied by 
harmless and beneficial microorganisms called commensal bacteria that live in 
symbiosis with the host. In order to tackle such an exposure and owing to the need of 
managing both commensal and harmful bacterial populations, our bodies have evolved 
to protect itself by developing the innate immunity and adaptive immune responses 
acting at both body surfaces and within immune hubs such as the peripheral lymph 
nodes (Murphy and Weaver 2017). The cells that assist in these processes are immune 
cells such as lymphocytes, macrophages, dendritic cells and different repertoires of 
cells that trigger effector mechanisms tailored to offer the most effective protection to 
these sites. For instance, within the mucosal epithelial cells there are intraepithelial 
lymphocytes (IELs) present (Fig.1.1) which are mostly T cells that maintain homeostasis 
and serve as a hub for barrier functions such as antigen interaction (Cheroutre, 2004), 
cytotoxic activity (Cheroutre et al.,2011) and regulation of both innate and adaptive 
responses (Sheridan and Lefrançois, 2010). To illustrate this with an example, the state 
of the immune system including the repertoire of cells and response during infection in 
the GI tract is shown in Fig. 1.1. When the body encounters a pathogen, the innate 
immune response is first triggered to detect and destroy the pathogen. Pattern 
Recognition Receptors (PRRs) such as Toll like Receptors (TLR) are present on the 
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surface of dendritic cells, macrophages and other immune cells that are capable of 
recognising molecules that are unique to bacteria, fungi and viruses. These molecules 
are called Pathogen Associated Molecular Patterns (PAMPs). Examples of PAMPs 
include lipoteichoic acid derived from the cell wall of Gram-positive bacteria, 
lipopolysaccharide (LPS) derived from the outer membrane of Gram-negative bacteria, 
zymosan derived from the cell wall of fungi and single or double-stranded RNA 
encoded within viral genomes. Another type of an innate immune sensory complex, 
comprised of Nucleotide-binding oligomerization domain (NOD) and other variable 
domains, are collectively called NOD like receptors (NLRs) which are present within the 
cytoplasm of host cells.  The NOD proteins are important in the detection of PAMPs 
derived from intracellular pathogens and in the activation of signalling cascades 
(Murphy and Weaver 2017).  
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Figure 1.1: Example of the immune system within the GI tract where immune cells are 
integrated into mucosal surfaces and secondary lymphoid organs ready to respond to 
pathogens. This figure adapted from Bron et al., 2012 shows the different layers of the gut 
and the immune cells they contain. Here, an infected state with bacterium is shown that 
involves various molecules such as antimicrobial peptides, antigens and PAMPs from the 
pathogen. The figure shows the outermost mucosal barrier followed by the epithelium that 
contains the TLRs at the surface. The epithelial layer also consists of the intraepithelial 
lymphocytes (IELs) that deliver the antigens to the Peyer’s patches. M cells in the underlying 
membrane then transport the antigens to dendritic cells and macrophages to further activate 
T cells and B cells leading to an active inflammatory response.  
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1.1.1 Toll-like receptor (TLR) 4  
Toll-like receptors (TLRs) are transmembrane proteins that consist of 18-25 copies of 
leucine-rich repeats (LRR) in the extracellular region (Fig. 1.2). The number of TLR-like 
genes expressed in different organisms varies with 10 being found in humans and 12 in 
mice. Each TLR has distinct ligands and is responsible for specific recognition of a single 
PAMP or set of PAMPs. PAMPs play a key role in activating the immune system and 
initiating the recruitment of immune cells. In mammals, TLRs are widely expressed in 
different innate and adaptive immune cells such as macrophages, dendritic cells, and B 
cells but are also expressed in other cells found at body surfaces such as epithelial and 
stromal cells. The activation of TLR receptors aids in stimulation of responses against 
pathogens (Murphy and Weaver 2017, p.88). Signalling is activated only upon 
dimerisation of TLRs or conformational changes in the dimer that are induced by 
binding of a ligand.  All mammalian TLR proteins have a TIR (Toll- IL-1 receptor) domain 
in their cytoplasmic tail. The TIR domains interact with other TIR- type domains which 
are usually present in accessory signalling molecules involved in subsequent steps of 
TLR signal transduction (Murphy and Weaver 2017). 
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Figure 1.2: A representation of mammalian TLRs. This figure from Murphy and Weaver, 2017 
shows mammalian TLRs that recognise a wide variety of distinct PAMPs and are found in 
different cellular locations. The figure shows nine of the TLRs expressed in humans and mice. 
The cellular localization and PAMP recognized by each receptor is also shown. TLRs are 
transmembrane proteins with 18-25 copies of leucine-rich repeats (LRR). For ease of 
representation, this figure displays only 9 LRRs which are illustrated using the small box-like 
structures. Some TLRs are localized within the cell membranes of many cells and are capable 
of detecting extracellular microbial PAMPs while others are found within endosomes which 
contain materials sampled from either the extracellular or intracellular compartments. While 
it is predicted that all TLRs form dimers, only those that form heterodimers are shown in 
dimeric form here.   
 
Toll-like Receptor 4 (TLR4) is one TLR that is most widely expressed by many cells. LPS, 
a significant component of the outer membrane of Gram-negative bacteria is one of 
the best characterised PAMPs which is recognised by the TLR4 receptor. Recognition of 
LPS by TLR4 results in the activation of a series of signalling pathways that leads to 
activation of transcription factors such as Nuclear factor-κB (NFκB) and Activator 
protein 1 (AP-1). Activation of these factors leads to the recruitment of active 
macrophages and other immune cells along with release of cytokines, chemokines, 
other chemical mediators and in some cases effector molecules. TLR4 activation 
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requires three other accessory molecules which are involved in the binding and 
sequestration of LPS. These include LPS-binding protein (LBP), myeloid differentiation 
factor 2 (MD-2) and cluster of differentiation 14 (CD14). LBP binds directly to the 
extracellular LPS and assists in the interaction with CD14 (Tobias et al., 1986, Wright et 
al., 1989). CD14 further facilitates the association of LPS with the MD-2/TLR4 complex 
for LPS recognition (Wright et al., 1990). TLR4 is incapable of binding to LPS 
independently hence, MD-2 is required for both- the trafficking of TLR4 receptor to the 
cell surface and recognition of LPS (Murphy and Weaver, 2017 p. 92). Together, the 
binding of LPS to this hetero-tetrameric complex initiates the activation of a series of 
signalling cascades (Gioannini and Weiss, 2007; Miyaki, 2007; Lu et al., 2008). A brief 
outline of the TLR4 activation pathway adapted from Miyaki, (2007) and Fitzgerald et 
al., (2004) is shown in Fig.1.3. After activation, the TIR domain of TLRs interacts with 
other TIR domains, and those domains are of adaptor molecules that are responsible 
for initiation of intracellular signalling. For mammalian TLRs, there are four adapters 
that are used: MyD88, TIRAP, TRIF and TRAM. Although most TLRs interact with 
MyD88 only or the MyD88/TIRAP pair, other TLRs like TLR3 use only TRIF; TLR2 
heterodimers (TLR2/1 and TLR2/6) use the MyD88/TIRAP or TRIF/TRAM. TLR4 
particularly uses both MyD88/TIRAP and TRIF/TRAM for signalling and gives rise to two 
types of signalling routes- MyD88- dependent and MyD88- independent pathways. 
Transduction of signals through these pathways activates a range of transcription 
factors such as NFκB and members of the activator protein 1 (AP-1) family like c-Jun. 
AP-1 proteins are activated through the mitogen- activated protein kinases (MAPK) 
pathway and will be discussed further later. The intracellular responses generated as a 
result of these cascades leads to the production of inflammatory cytokines, 
chemotactic factors and antimicrobial peptides. It also promotes maturation of antigen 
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presenting cells (Lu et al., 2008). At the same time, the host is unresponsive to LPS 
from commensals that reside in the epithelial surfaces such as the GI tract since 
gastrointestinal epithelial cells do not express TLR4 at the surface of the lumen under 
normal condition (Backhed and Hornef, 2003). To protect the host from opportunistic 
infections at submucosal surfaces by commensals during an invasion due to injury for 
example, TLR4 expression occurs at those surfaces. Other studies have also 
demonstrated that differences in the Lipid A moiety of LPS distinguish commensals 
from pathogens and commensal LPS either antagonise TLR4 or simply do not trigger a 
response (Munford and Varley, 2006).   
 
 
Figure 1.3: Two routes of TLR4 signalling after LPS administration. This figure adapted 
from Miyaki, (2007) and Fitzgerald et al., (2004) shows a brief overview of the intermediate 
steps in TLR4 signalling pathway occurring after TLR4 expressing cells are treated with LPS. 
LBP, CD14 and MD-2 are essential cofactors in the activation of the TLR4 receptor complex. 
After activation of TLR4, the transduction pathway bifurcates into MyD88 dependent and 
MyD88 independent signalling intermediates that result in the promotion of pro-
inflammatory cytokines and type I interferons. 
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1.1.2 Adaptive immune response and dysregulation of the immune system 
If the innate immune response fails to control and eliminate a foreign microbe or if a 
previously encountered pathogen is detected, the adaptive immune system is 
activated that ultimately results in the release of cytokines by innate immune cells that 
promote and polarize the adaptive immune responses into routes which encourage 
distinct immune outcomes. These outcomes are determined by the coordination of 
three major Innate Lymphoid cell (ILC) responses- ILC1, ILC2, ILC3 and T cell effector 
modules- TH1, TH2, TH17 that collectively classify as Type 1, Type 2 and Type3 
responses respectively. Type 1 response is directed towards intracellular pathogens 
that lead to the action of TH1 cells, ILC1s, macrophage activation, recruitment of 
Natural Killer (NK) cells and release of IFN-γ. Type 2 responses are mainly targeted 
towards elimination of parasitic organisms that involve the activity of ILC2s, TH2 cells, 
eosinophils, basophils and mast cells leading to antibody production, antigen-specific 
activation and recognition. Type 3 responses are triggered against extracellular 
bacterial and fungal infections which are characterised by the activity of ILC3s, TH17 
cells that opsonises IgG and recruits neutrophils (Murphy and Weaver, 2017, p. 27, 
p.451, Calandra and Roger, 2003). At the same time, the immune system is capable of 
distinguishing between pathogenic and non-pathogenic encounters which are 
mediated by regulatory T cells (Tregs). Tregs maintain self- tolerance thus preventing 
autoimmune diseases (Sagakuchi et al., 1995, Wang et al., 2007, Piao et al., 2008, 
Wang et al., 2008).  They also maintain tolerance to: antigens derived from food (Chen 
et al., 1994); foetus by carrying mother (Aluvihare et al., 2004); and commensal 
microbiota thus preventing their elimination (Dembic, 2008). During these processes, 
complex sets of secreted immunoregulatory molecules and co-stimulatory molecules 
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are released from the cells to the surfaces. Most of these molecules are small proteins 
called cytokines and play a fundamental role in regulation of immune responses and 
coordination of humoral and cellular arms of the immune system (Calandra and Roger, 
2003).  
In most circumstances these activities result in clearance or control of the potential 
pathogens within a minutes or hours of entry into the body without disruption of 
homeostasis or the development of overt symptoms (Calandra and Roger, 2003). 
However in the rare instances when disruption of the homeostasis and function of the 
immune machinery occurs, undesirable or dysregulated immune responses can 
develop into loss of barrier function (Mankertz and Schulzke, 2007). Loss of barrier 
function can lead to systemic infections or pathogen induced inflammation and 
diarrhoeal disease which are a major cause of deaths in the world. For example, 
Salmonella is a most commonly occurring food borne pathogen that has been 
associated with the highest impact on disability in human health (Kirk et al., 2015; 
Scallan et al., 2015) and the most number of deaths (Havelaar et al., 2015). There are a 
large variety of bacterial, viral and protozoal pathogens whose infections can cause 
these effects. In addition there are groups of pathogens such as parasitic nematodes 
which establish long-term associations with the tissues of mucosal surfaces such as the 
GI tract. While they generally do not cause lethal infections they induce insidious 
pathological states that either have long term effects on adolescent development or 
adult disability (Stepek et al., 2006). A dysregulation of one or more components of the 
immune system can lead to development of a range of outcomes including 
immunodeficiency disorders, chronic inflammation and in some instances cancer 
(Murphy and Weaver 2017, p. 533, Wen et al., 2008, Lee et al., 2010, Berer et al., 
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2011, Wu et al., 2010). Chronic inflammatory states are now recognized as a key 
preceding factor to the development of malignancies (Brey et al., 2012) and within the 
GI tract the dysregulated inflammatory responses have been linked to progression of 
gastric and colon cancer (Bucala and Donnely, 2007, Gordon-Weeks et al., 2015). 
Within the innate immune system, defects in the signalling cascades underlying PRR 
activation can give rise to chronic inflammation or immunodeficiency. Recently, 
several master regulators of PRR activation including a protein called Macrophage 
Migration Inhibitory Factor (MIF) which is a pleotropic cytokine, chemokine and 
hormone have been linked to the development of both chronic inflammation and 
cancer (de Jong, 2001, Murakami et al., 2001). 
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1.2 Macrophage Migration Inhibitory Factor  
Macrophage Migration Inhibitory Factor (MIF) is one of the first cytokines to be 
discovered about 5 decades ago. Produced by T-lymphocytes, it was shown to inhibit 
the random migration of macrophages (David, 1966, Bloom and Bennet, 1966). It is 
pleotropic in nature and has chemokine and hormone like characteristics. The MIF 
gene (Fig. 1.4) is located at Chromosome 22 in the human genome and Chromosome 
10 in the mouse genome. This gene is found to be highly conserved within vertebrates. 
Many MIF homologues have also been found across the eukaryotes including species 
of plants and parasitic organisms (Calandra and Roger, 2003, Bernhagen et al., 1994). 
The presence of MIF and its homologues across various species indicate that it has a 
significant conserved biological role (Calandra and Roger, 2003). Although T 
lymphocytes were initially thought to be the main source of MIF, it was eventually 
found that other cells such as macrophages, neutrophils, eosinophils, mast cells, 
basophils, blood dendritic cells and B cells also express and secrete MIF (Baugh and 
Bucala, 2002, Lue et al., 2002) 
 
 
Figure 1.4: A schematic representation of the human MIF gene. The MIF gene comprises of 
three exons (highlighted in green) and two introns (shown in pink). The regulatory region at 
the 5’ end consists of several consensus DNA-binding regions such as that of transcription 
factors like activator protein- 1 (AP-1), nuclear factor κB (NF-κB), ETS and GATA. However, 
how these DNA-binding sites interact with other proteins and regulate biological activities is 
not known. 
 
Calandra and Roger, 2003. NATURE REVIEWS | IMMUNOLOGY  
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The MIF protein has a molecular weight of 12.5 kDa and is secreted despite the fact it 
lacks the N-terminal endoplasmic reticulum (ER) targeting sequence. It is constitutively 
expressed in a wide variety of cells (Bernhagen et al., 1994). One of the unique 
characteristics of mammalian MIFs is that they possess two distinct enzymatic 
activities, acting as both a tautomerase and an oxidoreductase. Structure function 
studies have shown that these enzymatic activities require the N-terminal Proline (P2 
in all MIFs) for tautomerase activity and the CXXC motif (Cys-56 and Cys-59 in 
mammalian MIF1) motif at the C-terminus for oxidoreductase activity (Rosengren et 
al., 1997, Kleeman et al., 1998). While most identified MIFs have the P2 and are 
predicted to have tautomerase activity many MIF-like proteins including some parasite 
derived MIFs lack the CXXC motif and thus would not be expected to exhibit 
oxidoreductase activity (Fig. 1.5). In mammals a second MIF-like protein D-
Dopachrome Tautomerase (D-DT)/MIF2 has been identified (Sugimoto et al., 1999, 
Merck et al., 2012) which possess the tautomerase activity but lacks one of the CX 
domain (Cys-59), thus having an incomplete CXXC domain and no detectable 
oxidoreductase activity (Fig. 1.5). 
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HsMIF1 
MmMIF1 
TsMIF1 
HsDDT 
MmDDT 
 
MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALC 
MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTNDPCALC 
MPIFTLNTNIKATDVPSDFLSSTSALVGNILSKPGSYVAVHINTDQQLSFGGSTNPAAFG 
MPFLELDTNLPANRVPAGLEKRLCAAAASILGKPADRVNVTVRPGLAMALSGSTEPCAQL  
MPFVELETNLPASRIPAGLENRLCAATATILDKPEDRVSVTIRPGMTLLMNKSTEPCAHL 
**:. ::**:    :* .: .      .   .** . : * :  .  : :. :.:*.*   
 1--------10---------20---------30---------40---------50---------60 
 
HsMIF1 
MmMIF1 
TsMIF1 
HsDDT 
MmDDT 
 
SLHSIGKIGGA-QNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA--
SLHSIGKIGGA-QNRNYSKLLCGLLSDRLHISPDRVYINYYDMNAANVGWNGSTFA-- 
TLMSIGGIEPS-RNRDHSAKLFDHLNKKLGIPKNRMYIHFVNLNGDDVGWNGTTF--- 
SISSIGVVGTAEDNRSHSAHFFEFLTKELALGQDRILIRFFPLESWQIGKIGTVMTFL 
LVSSIGVVGTAEQNRTHSASFFKFLTEELSLDQDRIVIRFFPLEAWQIGKKGTVMTFL  
: *** :  :  ** :*  :   * ..* :  :*: *.:  ::. ::*  .:.:    
 ---------70---------80---------90---------100---------110----115 
 
Figure 1.5: Conservation of MIF1 and D-DT (MIF2) across mammalian and parasitic nematode 
species. Protein sequences of mammalian and parasite MIF1 and D-DT (MIF2) taken from NCBI 
(gene) and aligned using the multiple sequence alignment tool Clustal Omega. Conserved amino 
acids between the species are marked with an asterix (*). Amino acids highlighted in yellow shows 
the tautomerase active site that is conserved across all species for both MIF1 and MIF2 while the 
oxidoreductase active site (CXXC) is shown in green that is conserved only between human and 
murine MIF1. Blue highlighted amino acids are conserved Cys59 between human and murine D-DT.  
 
The crystal structure of human MIF was characterised using X-ray Crystallography by 
Sun et al., (1996). As seen in Fig. 1.6, MIF is a homotrimer and contains one β sheet 
with two additional β strand and two anti-parallel α-helices. The trimeric structure of 
MIF is arranged to form an inner, hydrophobic pore that is crucial for the maintenance 
of its enzymatic activities. However in one study, it was found that under certain 
physiological conditions, MIF can also exist in monomeric and dimeric forms (Sun 
et.al., 1996) but how this affects its biological functions is not known. Structure and 
function studies have established that the C-terminus of MIF contains the motif 
responsible for chemokine receptor binding which results in the promotion of 
inflammatory processes by acting as a chemoattractant  (Kraemer et al., 2011) and for 
binding to CD74 which is a putative receptor of MIF  (Leng et al., 2003).  
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Figure 1.6: The three dimensional structure of human Macrophage Migration Inhibitory 
Factor (MIF). The image adapted from Gordon-Weeks et al., 2015 shows the tertiary protein 
structure of MIF in their monomeric and trimeric forms (top, PDB ref: 2WKF  and bottom, 
PDB ref: 1MIF respectively). The oxidoreductase catalytic site can be seen in blue in the 
monomer while the CXCR2 motif- a chemokine receptor of MIF is shown in red in both the 
monomer and trimer. Proline 1 is displayed in yellow for both the monomer and trimer which 
confers the tautomerase activity to MIF. The trimeric structure shows the amino acids 
Aspartic acid-44 (orange) and Arginine-11 (blue) that are important for the chemoattractant 
properties of MIF. Individual monomers in the trimeric form are represented by cyan, purple 
and green.  
 
  
Gordon-Weeks et al., 2015 
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In terms of biological functions and immunological activities, MIF was initially 
identified because of its chemoattractant properties for various leucocyte subsets. 
Later it was found that when mice are injected with endotoxin (LPS), MIF is released 
from the anterior pituitary gland and adrenal cortex like a hormone, antagonising 
glucocorticoid activity and promoting systemic endotoxemia (Xia et al., 2005, Calandra 
and Roger, 2003). The adrenal cortex significantly contributes to the systemic levels of 
MIF present maintaining both basal concentration and elevating levels of MIF post LPS 
administration (Bernhagen et al., 1993). Cells such as macrophages and monocytes can 
also secrete large quantities of MIF when treated with LPS (Calandra et al., 1994) 
which is linked to control of local inflammatory responses. However, the basis for how 
MIF exerts its pro-inflammatory activities remained a mystery until relatively recently 
which will be discussed in detail further below. 
  
  
Gordon-Weeks et al., 2015 
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1.3 Role of MIF in Innate Immunity 
1.3.1 Influence of MIF in inflammation 
Studies have shown evidence of MIF being directly or indirectly involved in the 
production of a large number of pro-inflammatory molecules in a wide variety of cell 
types. These include cytokines such as IL-1β, IFN-γ, tumour-necrosis factor (TNF), IL-2, 
IL-6, IL-8 and macrophage inflammatory protein 2 (Calandra et al., 1994, Calandra et 
al., 1995, Bacher et al., 1996, Donnelly et al., 1997, Makita et al., 1998), nitric oxide 
(NO) (Bozza et al., 1999, Bernhagen et al., 1994), as well as Cyclooxygenase 2 (COX2) 
and other elements of the arachidonic acid pathway (Mitchell et al., 1999, Mitchell et 
al., 2002). Thus, MIF seems to have a crucial role in the inflammatory response after 
exposure to pathogenic molecules, other pro-inflammatory cytokines and antigen-
specific stimulation. Since MIF is released not only as a cytokine but also as a hormone 
from the anterior pituitary gland, MIF levels can systemically aggravate an 
inflammatory response. For example, in one study, mortality in patients with sepsis 
was correlated with high MIF levels (Chuang et al., 2014, Bozza et al., 2004, Chuang et 
al., 2007). Studies in mice showed that inhibition of MIF protected the mice from lethal 
toxaemia post LPS administration (Bernhagen et al., 1994). These studies show that 
inhibition of MIF could control inflammatory responses and thus can have therapeutic 
potential in some inflammatory diseases. With such observations, an unexpected 
finding was that glucocorticoid hormones promoted MIF secretion rather than 
inhibiting it (Calandra et al., 1995). MIF acts as an antagonist to glucocorticoids thus 
inhibiting its anti-inflammatory function and the effects of other immunosuppressive 
cytokines (Santos et al., 2001, Bacher et al., 1996). In in vitro studies, it was found that 
MIF counter-regulated glucocorticoid impedance of IL-8, IL-6, IL-1 and TNF production 
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in peripheral blood mononuclear cells (Calandra et al., 1995). This behaviour was 
confirmed in mice experiments related to endotoxaemia and antigen-induced arthritis 
(Leech et al., 2000). It was also found in various studies that along with glucocorticoids, 
levels of circulating MIF increased during inflammation and infection (Calandra et al., 
2000, Calandra et al., 1995, Beishuizen et al., 2001). MIF’s involvement with TLR4 and 
intermediates such as the mitogen- activated protein kinases (MAPK) that are crucial 
mediators of pro-inflammation has been evidenced and are elaborated in further 
detail below.  
1.3.2 Modulatory activities of MIF in TLR4 signalling and the MAPK Pathway 
MIF is constitutively expressed in many cells including macrophages, which is unusual 
for other cytokines which are known to modulate pro-inflammatory immune reactions. 
A number of studies have shown that MIF can modulate TLR4 signalling in immune 
cells (Roger et al., 2001, Sivaram et al., 2012) however the exact mechanism underlying 
this activity has not been fully elucidated. Studies with macrophages lacking the MIF 
protein revealed that those cells had reduced response to LPS but a normal response 
to other stimuli. The hyporesponsiveness observed in MIF deficient cells was 
subsequently shown to arise from the downregulation of TLR4 receptor which 
subsequently lead to lower downstream pro-inflammatory cytokine production (Roger 
et al., 2001, Roger et al., 2003). In the study by Calandra and Roger (2003), MIF was 
shown to upregulate TLR4 expression by controlling the activity of the ETS 
transcription factors which are important for the transcription of TLR4 gene in mice. 
Thus, it was thought that MIF assists the cells that are in the forefront of the pathogen 
defence system such as macrophages and allows rapid detection of endotoxin carrying 
bacteria. This was validated by another finding where MIF- deficient mice were unable 
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to inhibit the growth of Salmonella typhimurium- an intracellular pathogen 
(Koebernick et al., 2002). Studies carried out later reported that there was reduced 
secretion of pro- inflammatory molecules such as IL-1β, TNF and Prostaglandin E2 
(PGE2) in the survival of MIF-deficient macrophages over wild type macrophages post 
LPS treatment (Mitchell et al., 2002). This provides an explanation to the constitutive 
expression of MIF by tissues and cells associated with external surfaces.  
However, in other studies of MIF which were not focused on TLR4 activity, MIF has 
been shown to modulate the activity of key signalling intermediates downstream of 
TRAF6 and TAK1 (Fig. 1.7) such as extracellular signal-regulated kinase (ERK) 1 and 
ERK2 of the MAPK family. Experiments using quiescent fibroblasts showed that MIF 
caused rapid activation of ERK1/ERK2 and was able sustain the activated and 
phosphorylated state in these kinases for up to 24 hours (Mitchell et al., 1999). 
Whether this also impacts on the activity of TLR4 in cells along with the transcriptional 
control of TLR4 expression has not been determined.  Mitogen-activated protein 
kinase (MAPK) pathways consist of conserved kinase molecules that regulate growth, 
differentiation, apoptosis and migration of cells (Dhillon et al., 2007). The triggering of 
ERK1/ERK2 by MIF was shown to be dependent on Protein kinase A and has been 
linked to increased enzyme activity of cytoplasmic phospholipase A2 (PLA2). This is 
fundamental because PLA2 acts as a crucial mediator for the initiation of the pro- 
inflammatory cascade leading to production of arachidonic acid followed by 
prostaglandins and leukotrienes. Glucocorticoids target PLA2 to diminish the 
inflammatory state and induce immunosuppressive effects. Thus, MIF may be able to 
antagonise glucocorticoid action via PLA2 through the ERK1/ERK2 pathway (Mitchell et 
al., 1999). There is also evidence of MIF inhibiting JUN-activation domain-binding 
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protein 1 (JAB1), a co-activator of AP-1 and a postulated intracellular receptor of MIF 
(Kleeman et al., 2000) that causes phosphorylation of JUN through activation of the 
JUN N-terminal kinase (JNK). AP-1 is a transcription factor that is known to be involved 
in cell survival and proliferation (Kleeman et al., 2000). This is a puzzling finding 
considering that it seems to contradict observations in other cell types where MIF has 
been shown to promote cell survival and proliferation.  
MIF has been shown to have high-affinity binding for CD74 (Leng et al., 2003) which 
may be involved in the cell kinetics and stimulation of pathways. Although the exact 
mechanism of how the signalling cascade proceeds is not known, it was observed that 
activation of the MAPK pathway by MIF was dependent on binding to CD74 and 
required a complete CD44 molecule (Leng et al., 2003 Shi et al., 2006). Studies provide 
evidence of elevated levels of MIF in tumour cell lines and primary tumours (Mitchell 
et al., 2000).  With findings on various activities of MIF in different pathways, remain 
several unanswered questions about how MIF may control aspects of TLR4 activation 
and inflammation. Figure 1.7 shows the three main receptors- TLR4, CD74 and TNF α 
receptor 1 (TNFR1) whose signal transduction cascades commonly intersect at the 
MAPK and lead to activation of transcription factors NFκB and AP-1 that initiate 
production of pro-inflammatory mediators and growth factors. This is important 
because MIF has displayed modulatory action on MAPK that was measured either by 
TLR4 receptor expression levels or production of pro-inflammatory molecules. 
Studying the effects of MIF within these pathways may help identify MIF interactions 
and lead to understanding of mechanisms through which MIF extends its behaviour.  
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                     (A)                               (B)                               (C) 
 
Figure 1.7: Potential intersection points of MIF signalling. This 
figure outlines the transduction pathway of three receptors TLR4 
(A), CD74 (B) and TNF α receptor 1 (TNFR1) (C). MAPKs are one of 
the proteins that are activated when these receptors are triggered 
with their ligands as shown ultimately leading to the triggering of 
NFκB and AP-1 that produce pro-inflammatory molecules. MIF has 
shown to modulate ERK1/ERK2 of the MAPK and bind strongly to 
CD74. 
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1.3.3 Pathogen derived MIF homologues 
MIF has been characterised from various parasites including the nematodes Trichinella 
spiralis (Pennock et al., 1998, Tan et al., 2001), Brugia malayi (Zang et al., 2002), 
malarial parasite Plasmodium falciparum (Cordery et al., 2007) and trypanosomatid 
Leishmania major (Richardson et al., 2009). It has been shown that these parasites 
secrete MIF in the infected host and modulate the activities of the host immune 
system.  For example, Plasmodium falciparum MIF was found to be secreted in the 
RBCs of the infected host and suppress activation of TLR4 (Cordery et al., 2007). 
Another parasite, Trichinella spiralis, secretes a MIF homologue called TsMIF1 which 
shares properties similar to that of human MIF1 such as the tautomerase activity (Fig. 
1.5), monocyte migration inhibition and chemotactic ability (Tan et al., 2001). T.spiralis 
larvae have been shown to secrete higher amounts of MIF than that present in the 
human plasma, which may affect the host’s monocyte migration and chemotactic 
actions (Tan et al., 2001). This is particularly important because newborn larvae (NBL) 
produced after T.spiralis infection invade the skeletal muscles and transform them into 
nurse cells (Despommier, 1975, Despommier, 1993), causing drastic tissue damage and 
impairment of functions. These nurse cells are a niche for this parasite to reside stably 
for long periods of time (Despommier, 1993). Thus, investigating the effects of TsMIF1 
will further our understanding on the influence of this parasite derived MIF homologue 
and its contribution to immune dysregulation during T.spiralis infections. 
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2.0 Aims 
The aim of this research was to expand our understanding of how MIFs may modulate 
the elements of TLR4 signalling. It has been known that human and murine MIF1 can 
upregulate the expression of TLR4 after LPS treatment. However, it has also been 
shown in other studies which are not focussed on TLR4 activity that MIF1 was capable 
of activating ERK1/ERK2 of the MAPK pathway. Hence, it is possible that MIF1 controls 
both the abundance of the TLR4 receptor and activation of TLR signalling components. 
In addition, in spite of having the distinct enzymatic activities of MIF1 well 
characterised, their contribution (if any) to the modulation of TLR signalling remains 
unexplored.  
The aim of this work was to further characterise the modulation of TLR4 activation by 
MIF1, specifically focusing on determining if it modulates signalling intermediates 
down-stream of the TLR4 receptor. To exclude the previously characterised effects of 
MIF on TLR4 transcription from our studies we will utilised a cell system where TLR4 
expression is not controlled by its endogenous receptor. Unfortunately, while 
recombinant human MIF1 is commercially available, testing within our and other 
laboratories have shown that it lacks both of its known enzymatic activities and shows 
very modest activity in cell chemotaxis assays. This has lead us to conclude it is not 
suitable for use in our studies.  Therefore, the specific aims of this study were: 
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1. To design and construct bacterial expression vectors that produce recombinant 
Mus musculus MIF1 and obtain purified and endotoxin-free protein.  
2. To validate the commercially available HEK 293 blue hTLR4 cell system 
(Invivogen). This is a HEK cell line that stably expresses all the functional 
components of the TLR4 receptor system. This includes TLR4, MD-2 and CD14 
along with a NFκB and AP-1 inducible reporter controlling the expression of the 
reporter, secreted alkaline phosphatase (SEAP). Wild-type HEK cells are not 
responsive to LPS, do not express TLR4, MD-2 or CD14, have minimal SEAP 
activity but do express the other downstream components of the TLR signal 
transduction pathway. 
3. To analyse the activity of enzymatically active recombinant murine MIF1 
protein using HEK-Blue™ hTLR4 to examine if MIF1 modulates TLR4 activation. 
As part of this study a MIF1 homologue derived from the parasite Trichinella 
spiralis (TsMIF1) which lacks the oxidoreductase activity found in murine MIF1, 
will be use as a comparator. 
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3.0 Materials and Methods 
 
3.1 Bacterial and Mammalian Cell culture 
The TOP10 Escherichia coli strain was used to perform all transformations in the 
cloning procedures. The BL21 Codon plus E. coli (Weiner et al., 1994, Statgene) strain 
was used for efficient expression of MIF1, The E.coli strain has been engineered to 
translate GC-rich open- reading frames by the inclusion of extra copies of tRNA genes 
(argU and proL) for recognition of arginine and proline codons.  All bacterial cultures 
were grown and maintained in one of the following media along with appropriate 
antibiotics: LB broth (40% tryptone, 20% yeast extract, 40% NaCl) , LB agar (24% 
tryptone, 12% yeast extract, 24% NaCl, 40% agar) and 2 X YT broth (52% tryptone, 32% 
yeast extract, 16% NaCl).  
The cell lines used for all TLR4 activity assays were HEK-Blue™ hTLR4 which are 
engineered HEK 293 cells transfected with TLR4, MD-2 and CD14 along with nuclear 
factor κB (NFκB) and activator protein 1 (AP-1) inducible reporter plasmid pNiFty2-
SEAP that produces secreted alkaline phosphatase (SEAP). HEK293 wild type (WT) cells 
stably transfected with pNiFty2-SEAP (HEK293 pNifty2-SEAP) were used as a control for 
all experiments. All HEK cells were cultured and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing high glucose (Sigma Aldrich) at 5% CO2. The DMEM 
was further supplemented with 10% FBS, 1% Penicillin/Streptomycin. Selection of HEK-
Blue™ Selection of HEK-Blue™ hTLR4 (Invivogen) was carried out using the antibiotics 
blasticidin, hygromycin and Zeocin™ at concentrations that have not been disclosed by 
the manufacturer (HEK-Blue™Selection). Selection of HEK293 cells transfected with 
pNifty2-SEAP was maintained by culture in 100 µg/ml zeocin containing media. HEK-
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Blue™ hTLR4 and HEK293 pNifty2-SEAP were used between Passage 1 and Passage 20 
(P1-P20). 
3.2 Plasmids, Media and Reagents  
Plasmids used for incorporation of the DNA insert and facilitating expression were 
pGEM®-T Easy Vector (Promega) and pET29b (Novagen). pGEM®-T Easy Vector carried 
the ampicillin resistant gene along with multiple cloning site within the α-peptide 
coding region of the β-galactosidase enzyme. Thus TOP10 transformants were selected 
using media containing ampicillin for selection of pGEM®-T Easy Vector and X-gal + 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) for blue-white selection.  The expression 
vector pET29b carried the kanamycin resistant gene which was used for selection of 
transformants. Cloning of murine MIF1 was performed so a His-tag comprised of six 
histidine amino acids was added in-frame to the C-terminus and this was used for 
subsequent protein isolation. The reporter plasmid pNifty2-SEAP was transfected into 
wild-type HEK293WT in order to use it as a SEAP assay reporter control. All reagents 
were used from Sigma-Aldrich, Thermo Fisher Scientific and Fisher Scientific UK unless 
otherwise stated.  
3.3 Cloning 
The cDNA encoding the sequence for murine MIF1 (MmMIF1) was previously obtained 
via reverse transcriptase PCR (RT-PCR) (Isolate II RNA Mini Kit, Bioline) and amplified 
with primers as described in Table 1 using Polymerase Chain Reaction (PCR) (Phusion® 
High-Fidelity DNA Polymerase, unit assay conditions: 25 mM TAPS-HCl (pH 9.3 @ 25°C), 
50 mM KCl, 2 mM MgCl2, 1 mM β-mercaptoethanol, 200 µM dNTPs including [3H]-
dTTP and 400 µg/ml activated Calf Thymus DNA). Primers were designed to include the 
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restriction sites Nde1 and Xho1 on the 5’ end and 3’end respectively, allowing the 
construction of an in-frame fusion of the MmMIF1 cDNA to the His-tag in the 
expression plasmid pET29b. The amplified MmMIF1 DNA sequence was poly A-tailed 
and then incorporated into the shuttle vector pGEM®-T Easy (Promega) by TA cloning 
and then ligating at 4oC overnight using T4 DNA ligase (New England Biolabs (NEB)). 
The plasmid-insert sequence was transformed into chemically competent E.coli 
(TOP10) using the standard CaCl2 method (See section 3.3.1), screened using PCR and 
confirmed by sequencing (University of Dundee, https://www.dnaseq.co.uk/). Colonies 
with confirmed MmMIF1 inserts in shuttle vector pGEM®-T Easy plasmid were picked 
and the plasmid was isolated using Monarch® Plasmid Miniprep Kit from NEB. Both the 
MmMIF1 insert and the expression plasmid pET29b (Novagen) were subjected to 
sequential restriction enzyme digestion with Xho1 and Nde1 (NEB) respectively to 
create compatible ends. After each digestion reaction, samples were checked on 1.5% 
agarose gel, excised to extract DNA and purified using Monarch® DNA Gel Extraction 
Kit from NEB. The purified insert and plasmid were ligated using T4 DNA ligase (NEB) at 
16oC overnight and transformed into chemically competent E.coli (TOP10) the next 
day. All reactions were carried out as per the manufacturer’s instruction. Successful 
MmMIF1-pET29b transformants were checked by PCR and validated by sequencing 
where the presence of 6x His epitope tag on the C-terminal was also confirmed. All 
PCR reactions for screening were carried out using Taq DNA Polymerase with Standard 
Taq Buffer (NEB), 2mM dNTPs, 10µM of each primer, 3µg of DNA template and set up 
as per the manufacturer’s instruction. All PCR products, ligation reactions and 
restriction digest reactions were checked using electrophoresis on 1.5% agarose gel 
containing 0.01% SYBR Safe DNA Gel Stain (Thermo Fisher Scientific). Samples were 
stained with 6X Purple Gel Loading Dye (NEB) and loaded on to the gel. The size of DNA 
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bands were checked using Quick-Load® Purple 2-Log DNA Ladder (NEB). Colonies 
successfully harbouring the MmMIF1-pET29b-6x His were picked and the plasmid was 
transformed into BL21 Codon plus E. coli bacterial expression system to further carry 
out protein expression. Fig. 3.1 shows a schematic layout of MIF1 in pET29b with the 
six histidines.  
 
 
 
Figure 3.1: A schematic representation 
of fusion MIF cDNA for Homo sapiens 
(Hs), Mus musculus (Mm) and 
Trichinella spiralis (Ts). 
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Table 3.1: A list of the sequence of primers used in the cloning procedure 
 
Sr. 
No. 
Primer name and sequence Use of sequence for corresponding 
plasmid/MIF 
1.  Forward primer: pET29b.F2   
5’- GTGATGCCGGCCACGATGCGTCC- 3’ 
 
Reverse primer: pET29b.R2  
5’- ATCCGGATATAGTTCCTCCTTTC- 3’ 
 
To screen pET29b plasmid and MIF1 
fusion sequence. 
2.  Forward primer: T7up   
5’- TAATACGACTCACTATAGGG- 3’ 
 
Reverse primer: T7down  
5’-GCTAGTTATTGCTCAGCGG- 3’ 
 
Commercially available primer 
sequences for pET29b plasmid.  
3.  Forward primer: Mm_MIF1 Fw  
5’-CATATGCCTATGTTCATCGTGAACACC- 3’ 
 
Reverse primer: Mm_MIF1 Rv  
5’-CTCGAGAGCGAAGGTGGAACCGTTCCAGCC- 3’ 
 
To amplify and screen the murine 
MIF1 DNA sequence 
4.  Forward primer: M13R  
5’-AGCGGATAACAATTTCACACAGGA- 3’ 
 
Reverse primer: M13L  
5’-CGCCAGGGTTTTCCCAGTCACGAC- 3’ 
Primer sequences for pGEMT shuttle 
vector. 
 
 
  
 
3.3.1 Escherichia coli Transformation  
Cells were made chemically competent using a protocol adapted from Inoue et al., 
1990. In a microcentrifuge tube, 10 µL of DNA was used per transformation 
experiment which was added to 100 µL of E.coli and placed on ice for 15 minutes. The 
transformation mixture was then heated exactly at 42o C for 45 seconds and promptly 
allowed to recover on ice for 2-5 minutes. The reaction mixture was subjected to 
addition of 250 µL of LB or 2 X YT broth and incubated at 37oC for an hour. The 
transformations were then plated onto the relevant antibiotic containing agar plates.  
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3.4 MmMIF1 expression  
3.4.1 Induction of proteins 
pET29b containing the MmMIF1 insert was transformed into BL21 Codon plus E. coli 
and used for subsequent protein expression and purification. Previously cloned and 
purified Trichinella spiralis (T.spiralis) MIF1 (Guiliano, unpublished) (TsMIF1) was used 
alongside MmMIF1 to compare the effects of mammalian MIF1 vs parasite MIF1 in the 
bioassays. Expression and production of soluble protein in BL21 Codon plus cells was 
tested using two methods which were induction with 50µM-1mM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) or culture in an auto-induction system with Overnight 
Express™ Instant TB Medium (Merck Millipore). If protein production was induced with 
IPTG, 5mL of the cell culture was first set up to grow overnight (o/n) with appropriate 
antibiotics. The next day, o/n culture was diluted 1:50 and added to fresh 25mL 2xYT 
media. Cells were allowed to grow until the optical density600 (OD600) reached 0.6-0.7. 
50µM-1mM of IPTG was added and left for cells to carry out protein production for 4-5 
hours. Cells were then centrifuged, pellets collected and frozen for subsequent 
processing and analysis. If the expression of MIF1 was induced by culturing in 
Overnight Express™ Instant TB Medium, large cultures were set up for an overnight 
incubation. The next day, cultures were spun down to obtain pellets which were either 
frozen or used immediately for processing and analysis.  For both the methods, 
samples were collected before and after induction and normalised for analysis. 
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3.4.2 SDS-PAGE and Western blot 
Presence of MIF proteins was visualised by Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) and coomassie blue staining. For initial analysis of total 
protein, OD normalised cell pellets were resuspended in 1X Laemmli buffer (10% 2 β- 
Mercaptoethanol, 90% loading mix) and briefly sonicated to lyse the cells. The lysed 
samples were then loaded onto a 15% polyacrylamide gel (3% stacking gel- 30% 
polyacrylamide mix, 1M Tris pH 6.8, 10% SDS, 10% APS, TEMED; 15% resolving gel- 
30% polyacrylamide mix, 1.5M Tris pH 8.8, 10% SDS, 10% APS, TEMED) and allowed to 
run by electrophoresis in 1X Tris/Glycine/SDS buffer (BioRad). The gel was later stained 
with Coomassie blue (50 % methanol, 10% acetic acid 40% H2O) and visualised on a 
Chemidoc (BioRad). For analysis of soluble and insoluble MIF protein, the cell pellets 
were resuspended in 1XPBS or 1XHBSS and sonicated to lyse the cells. Samples were 
centrifuged and the supernatant was collected which contained the soluble fraction of 
the protein while the cell pellets contained the insoluble fraction. 4X Laemmli buffer 
was added to the soluble fraction for a final concentration of 1X Laemmli buffer while 
the insoluble fraction was treated with 1X Laemmli buffer. The samples were loaded 
on to 15% polyacrylamide gel and allowed to separate by size by electrophoresis. The 
gels were stained with Coomassie overnight, destained the next day with destaining 
solution (40% methanol, 10% acetic acid, 50% H2O) and visualised on Chemidoc. 
Protein ladder, Precision Plus Protein™ Dual Color Standards (BioRad) was used as a 
protein marker. 
To confirm the presence of the His-tagged MmMIF1, western blot analysis was 
performed using a HRP conjugated anti-his tag antibody (Monoclonal Anti-
polyHistidine, A7058 Sigma  Aldrich).  SDS-PAGE was conducted with proteins as 
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previously described and proteins from the gel were transferred onto a nitrocellulose 
membrane through a semi-dry transfer (Trans-Blot® Turbo™ Transfer System, Bio-Rad). 
After transfer, the membrane was blocked with 5% milk in 1 X PBS to prevent non-
specific binding of the antibody. The membrane was washed with 1x TBST (0.01M Tris, 
0.14M NaCl, 0.05% Tween 20, pH 8.0) and incubated overnight (o/n) with the anti-his 
antibody that was added at a concentration of 1:3000 to 5% milk in PBS.  On the 
following day, the membrane was washed three times with 1xTBST and visualized with 
Pierce™ ECL Western Blotting Substrate (1:1 Thermo Fisher Scientific) on a Chemidoc 
analyser (BioRad).  
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3.5 Isolation and purification of MmMIF1 
3.5.1 Isolation of recombinant MmMIF1 by Ni+ affinity chromatography   
The His tag within the recombinant MmMIF1 protein was used for initial purification 
via Ni+ affinity chromatography. For small scale purification, His SpinTrap columns (GE 
Healthcare) were used whereas for large scale protein purification, 1 mL Protino® Ni-
NTA Column (Macherey- Nagel) was used on the ÄKTAprime plus (GE Healthcare). 
Proteins were induced with 50μM IPTG and pellets were collected after 4-5 hours. The 
following day, cell pellets were resuspended in binding buffer (20 mM sodium 
phosphate, 500 mM NaCl, 5 mM imidazole, pH 7.4), mechanically lysed via sonication 
and centrifuged to separate the soluble and insoluble material. The supernatants 
containing soluble protein were collected for purification either with His SpinTrap 
column (small scale for testing) or the ÄKTAprime plus (large scale). For The His 
SpinTrap columns, micro-centrifugation was carried out at 7000 x g.  The mini-columns 
were first centrifuged to remove the storage liquid and equilibrated using 600µL of 
binding buffer. Post equilibration, 600 µL of sample was applied to the column and 
centrifuged for 1 minute. The column was washed using binding buffer and eluted 
using 200 µL elution buffer (20 mM sodium phosphate, 500 mM NaCl, 500 mM 
imidazole, pH 7.4). The step was repeated resulting in two 200 µL fractions of purified 
protein samples which was measured (Absorbance 260/Absorbance 280) using Nano 
drop 1000 (Thermo Scientific).  
For the ÄKTAprime plus, the same binding and elution buffers were used. Soluble 
fractions were resuspended in binding buffer to inject into the system. The system was 
programmed to run a 60 minute cycle and the breakpoints can be seen in table 3.2. 
The other key parameters of the machine were: 1 mL/min flow rate or 0.5 mL/min 
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during injection of sample; 5 mL collection fraction when the slope of the UV peak was 
≤ 500 mAu (milli arbitrary unit). These breakpoints allowed washing and elution of the 
sample efficiently and eluted fractions were collected in the fraction collector that 
contained isolated MmMIF1 protein. 
Table 3.2: The breakpoints of the programme used on the ÄKTAprime plus for the isolation 
of MmMIF1 using Ni+ affinity chromatography  
 
Sr. 
No 
Time (in 
minutes) 
Action Flow position Concentration of 
elution buffer (in %) 
1. 0 Washing Load 0 
2. 8 Washing Load 0 
3. 10 Washing Inject 0 
4. 20 Washing Inject 0 
5. 30 Washing Load 0 
6. 30.1 Elution Load 100 
7. 40 Elution Load 100 
8. 40.1 Elution Load 100 
9. 50 Washing Load 0 
10. 60 Washing Load 0 
 
3.5.2 Buffer exchange and removal of excess salts 
To obtain MmMIF1 protein free from salts and imidazole, Amicon Ultra-15 (Merck, 
UFC900308) with a nominal molecular weight limit (NMWL)/ pore size of 3kDa was 
used. The NMWL allowed retention of the high molecular weight MmMIF1 protein 
(12.5 kDa) in the membrane bed whilst removing the lower molecular weight 
contaminants including salts and imidazole. Briefly, 15mL of sample was added to the 
filter and centrifuged at 4000 x g for 30 minutes. After multiple runs, the concentrated 
sample was washed three times with 50 mM of Tris buffer, pH 8.0 and resuspended in 
a final volume of 2.4 mL of the same buffer. This buffer exchange was necessary for 
the subsequent anion exchange chromatography. 
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3.5.3 Removal of residual endotoxin by anion exchange chromatography 
Residual endotoxin is one of the most common contaminants of recombinant proteins 
produced in bacterial systems. Removal of endotoxin was essential and crucial for the 
experiments conducted within this study since effect of the MIF protein was being 
examined after co-administration with LPS. Residual endotoxin was removed from 
purified MmMF1 by anion exchange chromatography (Pierce Strong Anion Exchange 
Spin Column, Mini, 90010). The buffer in which the protein was resuspended after 
Amicon filtration conferred a neutral charge to the protein thus effectively allowing 
the capture of negatively charged endotoxin by the positively charged resin contained 
within the column. Briefly, the column was washed with 50mM Tris, pH 8.0 buffer and 
centrifuged between 5000 to 7000 rpm. 400 μL of sample was loaded onto the column 
and centrifuged at the same speed. The flow through in the tube contained MmMIF1 
protein which was collected and pooled together after each column run.   
3.6 Bicinchoninic acid (BCA) assay  
For accurate quantification of purified MIF protein, Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific) was used. Protein standard BSA ranging from 2000 µg – 25 
µg was prepared and used to generate a standard curve. Samples were diluted as 
necessary to fit into the standard curve. The microplate procedure was used where 
190 µL of working reagent was added to 10 µL of each sample was added per well, 
shaken to mix and incubated for 30 minutes at 37oC. The working reagent was prepare 
using Reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1M sodium hydroxide) and Reagent B (4% cupric sulfate) in a 50:1 
ratio. Post incubation of the samples, the absorbance was measured at OD562 using a 
multi-mode microplate reader (BioTek, Synergy™ HTX). 
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3.7 Tautomerase enzyme assay 
To validate the presence of enzymatically active MmMIF1 at different stages of 
purification, the tautomerase assay adapted from Kudrin et al., 2006 was used. Briefly, 
20µL of 10mM L-dopa methyl ester and 20µL of 20 mM sodium periodate was added 
to 160µL of Buffer A (Potassium phosphate, 0.2% Tween 80). 4-6 µL of MIF was added 
along with 20 ng/mL of TsMIF1 as a positive control. The absorbance of the samples 
was immediately measured at OD475 every 45 seconds for 5 minutes at exactly 30
o C 
using a microplate reader.    
3.8 Limulus Amebocyte Lysate (LAL) assay  
To quantify the presence of any residual endotoxin in the purified recombinant 
proteins, the LAL assay (Pierce™ LAL Chromogenic Endotoxin Quantitation Kit, Thermo 
Fisher Scientific, 88282) was performed on the purified protein using a microplate 
procedure.  All steps were carried out at a temperature of 37o C. Briefly, the microplate 
and samples were equilibrated for 10 minutes. 50µL of each standard and unknown 
sample was added to the wells and incubated for 5 minutes. 50µL of the LAL reagent 
was added to the plate, shaken and incubated for exactly 10 minutes after which 
100µL of the substrate solution was added. The plate was shaken and incubated for 
another 6 minutes. To stop the reaction, 50µL of 25% acetic acid was added, plate 
shaken to mix and read at OD410. 
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3.9 Assessment of the effects of MIF1 on TLR4 activation  
Cells (HEK-Blue™ hTLR4 at, HEK293 pNifty2-SEAP and HEK293 WT) were seeded in HEK-
Blue™ Detection media or phenol red free Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% FBS, 1% Penicillin/Streptomycin at 5 x 104 cells/mL in 
a 96-well plate and then stimulated with LPS (from Escherichia coli O111:B4 L4391, 
Sigma Aldrich), TNF α (Biolegend), TsMIF1, MmMIF1 or pharmacological inhibitors  
such as Polymyxin B sulfate (PMB) (Acros Organics) prepared in 1x DPBS. Within each 
assay there were a minimum of three experimental replicates and each assay was 
repeated a minimum of three times (n=3).  The final volume in each well was 200µL. 
Two methods for measuring secreted alkaline phosphatase in the culture supernatants 
were validated and used interchangeably through the study: the- p-Nitrophenyl 
phosphate (pNPP) assay and commercially available HEK-Blue™ Detection media.  
For the LPS assay, cells were immediately stimulated after seeding with 20 µL/well of 
different Lipopolysaccharide (LPS) (Sigma Aldrich) concentrations (0.1 ng/mL- 1000 
ng/mL) with or without 1 µg/mL Polymyxin B sulfate (PMB) (Acros Organics). For 
bioassays with MIF1,  different wells containing HEK-Blue™ hTLR4 were immediately 
treated after seeding with 0.5 ng/mL, 1 ng/mL or 10 ng/mL of LPS, co-administered 
with different MIF1 (either TsMIF1 or MmMIF1) concentrations (0.01 µg/mL, 0.1 
µg/mL). Treatment with 100 ng/mL of TNF α (Biolegend) was used as a positive control 
for triggering NFκB and AP-1 activation. HEK293 pNifty2-SEAP cells treated with 
100ng/mL TNF α were used as an activation control for NFκB reporter plasmid. SEAP 
activity was measured 20 hours after treatment with one of the two methods. With 
the pNPP method, a 1:3 ratio of Alkaline Phosphatase (ALP) buffer (10mM Tris-HCl, 
150mM NaCl, pH 8.0) and pNPP solution (2.5 mg/ml pNPP in 100 mM diethanolamine, 
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150 mM NaCl, 2 mM MgCl2, pH 9.5) was prepared and 100 µL was added to 50 µL of 
each sample. The plates were incubated for 20 minutes at 37oC and 5% CO2 and the 
absorbance was read at OD405 on a multi-fold microplate reader (BioTek, Synergy™ 
HTX). When HEK-Blue™ Detection media was used, the plate was shaken after 20 
hours and SEAP activity was measured at OD620-655 using the same reader.  
3.10 Generation of single cell clones  
To produce a control reporter strain, HEK293 WT cells were transfected with a 
reporter plasmid found in the HEK-TLR4-Blue cell line, pNiFty2-SEAP using jetPRIME® 
transfection reagents (Polyplus transfection). Briefly, WT HEK293 cells were seeded in 
a 6-well plate at a density of 2.5 x 105 cells per well in 2 mL of Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% FBS, 1% Penicillin/Streptomycin 
(standard media). The following day, a transfection mix consisting of 200 µL of 
jetPRIME® buffer and 4 µL of jetPRIME® for every 2 µg of DNA was prepared and 
added dropwise to the seeded cells. The plate was shaken gently to mix and placed in 
the incubator. Cells were maintained in standard media for two days before subjecting 
them to selection. From the third day onwards, cells were maintained under zeocin 
selection in DMEM media with 10% FBS, 1% Penicillin/Streptomycin. Initially the 
polyclonal line transfected with 1 µg of reporter plasmid were used as NFκB activation 
control to determine if MIF recombinants modulate activation of NFkB in a TLR4 
independent manner. Single cell clones were later generated from the selected 
polyclonal population of HEK293 WT transfected with pNiFty2-SEAP.  Cells were 
seeded at a density of 0.5 cell/well or 1 cell/well in standard media. After 
approximately two weeks, wells containing single cell clones were isolated, subjected 
to selection with zeocin and tested for reporter activity using the NFκB inducer TNFα. 
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3.11 Statistical Analysis  
The data obtained from experimental procedures were analysed using GraphPad Prism 
version 3.0 or version 4.02. Datasets were examined for normality of distribution using 
Column Statistics. Significance of statistical analysis was evaluated using Students T-
Test or One-way ANOVA for parametric data while Kruskal Wallis test, Mann-Whitney 
or Wilcoxon Signed-rank was used for non-parametric data. The Bonferroni Post Hoc 
test was used to compare multiple columns while the Dunnet’s Post Hoc Test was used 
to compare each column with the control. Data was considered statistically significant 
at P value of ≤0.05.  
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4.0 Results 
4.1 MmMIF1 cloned into pET29b and obtained in BL21 Codon plus cells  
MmMIF1 (Mus musculus MIF1) cDNA was successfully subcloned into pGEM-T and 
then cloned into the expression vector pET29b. The expression vector MmMIF1-
pET29b was then transformed into E.coli BL21 Codon plus (Fig. 4.1). Sections I, II and III 
of fig. 4.1.A show the PCR amplicons verifying that the MmMIF1 was successfully 
cloned into pET29b by using three different set of MmMIF1 specific and vector specific 
primers: I) MmMIF1 insert specific primers (expected size: 354 bp); II) pET29b plasmid 
specific primers (expected size: 663 bp); III) pET29b forward primer and MmMIF1 
reverse primer (expected size: 500 bp). As seen from Fig. 4.1.A, the bands correspond 
approximately to the expected size which confirms the ligation of MmMIF1 into 
pET29b. Sequencing results (Fig. 4.1.C) further confirmed the presence of the MmMIF1 
insert with the adjacent His-tag in pET29b. 
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Figure 4.1: MmMIF1 was successfully cloned into pET29b. 
A: L- 2-log DNA ladder. 1.5% gel showing PCR products with I1- I4: MmMIF1 specific 
primers, ~354bp; II1-II4: pET29b specific primers, ~663 bp; III1- III5: pET29b forward 
and MmMIF1 reverse primers, ~500 bp; I5, II5, III5: no-DNA control. B: BL21 Codon plus 
E.coli transformed with the pET29b-MmmIF1 construct (I) and no-plasmid control (II). 
C: Expected (subject) and obtained (query) sequences aligned using BLAST and found 
to be 100% identical (% highlighted in green) for the MmMIF1 sequence and the His tag 
(highlighted in red) in pET29b.  
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4.2 Expression, isolation and purification of MmMIF1 
4.2.1 Soluble, enzymatically active MmMIF1 is expressed by the E. coli strain BL21 
Codon plus  
Induction of MmMIF1 expression in BL21 Codon plus with either 1000μM or 50μM of 
IPTG produced soluble protein (Fig. 4.2). However recombinant protein expression 
using Overnight Express media did not seem to induce the same level of expression as 
seen in Fig. 4.2.C and 4.2.D. Coomassie stained 15% polyacrylamide gel in fig. 4.2.A 
shows the total protein induced by both IPTG and overnight express media. Samples 
were OD normalised and equal volumes of sample were loaded onto the gel, thus 
levels of expression were directly comparable. As seen from Fig. 4.2.A, lanes 4 and 8 
show a distinct band at approximately 12.5 kDa. This band is absent in the pre-
induction controls (lanes 3 and 7) which confirm MmMIF1 expression upon induction. 
BL21 Codon plus containing pET29b without the MIF insert was used as a negative 
control for all experiments as seen in Fig. 4.2 to confirm the 12.5 kDa band that 
corresponds to MmMIF1. Coomassie analysis of the soluble and insoluble fraction of 
total protein can be seen in fig. 4.2.B and 4.2.C. Upon IPTG induction, MmMIF1 was 
found to express in both, the soluble and insoluble fraction similar to that of the 
positive control Trichinella spiralis MIF1 (TsMIF1) (Fig. 4.2.B). However, when induced 
with Overnight Express media, MmMIF1 expression was observed only in the insoluble 
fraction (Fig. 4.2.C, lane 8). In order to isolate the recombinant protein of interest from 
the insoluble fraction, additional procedures such as denaturing and refolding would 
need to be performed. To facilitate a simpler method for isolation of MIF1 protein, it 
was essential for expression of MIF1 in the soluble fraction. Western blot analysis (Fig. 
4.2.D) using anti-His-tag antibody confirmed successful MmMIF1 expression in the 
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soluble fraction. These results indicate that induction with IPTG was the best method 
for producing MmMIF1 and subsequent large-batch cultures were induced using this 
method. 
  
    A 
 
 
      B 
 
 
    C 
 
 
      D 
 
Figure 4.2: BL21 Codon plus cells express murine MIF1 in the soluble fraction. A-C: 
Coomassie- stained polyacrylamide gels, D: Western blot. A: Expression of MmMIF1 in total 
protein with 1mM IPTG or Overnight Express media pre (-) and post (+) induction. 1,2,5,6: 
pET29b in BL21 Codon plus without MIF insert; 3,4,7,8: MmMIF1pET29b. B: MmMIF1 
expression in the soluble and insoluble fraction. 1: soluble pET29b without MIF insert, 2: 
insoluble pET29b without MIF insert; 3: soluble MmMIF1, 4: insoluble MmMIF1; 5:  soluble 
TsMIF1 (positive control), 6: insoluble TsMIF1 (positive control). C: Comparison of MmMIF1 
expression with IPTG and overnight express media in the soluble and insoluble fraction. 1, 5: 
soluble pET29b without MIF insert and 2, 6: insoluble pET29b without MIF insert; 3,7: soluble 
MmMIF1 and 4,8: insoluble MmMIF1. D: Western blot confirming MmMIF1 expression in the 
soluble fraction with anti-his-tag. Control is pET29b without MIF insert. 
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4.2.2 MmMIF1 can be purified from the soluble extracts of E. coli BL21 Codon plus   
MmMIF1 was isolated from the soluble fraction of the bacterial protein lysates using 
Fast protein liquid chromatography (FPLC) (ÄKTA Prime Plus) affinity chromatography 
and purified by filtration and anion exchange chromatography. Eluted fractions 
containing MmMIF1 can be seen in Fig.4.3. Lane 1 in Fig. 4.3.A shows total protein 
after induction while lanes 2-7 show isolated MmMIF1 obtained from sequential 
purification runs on the ÄKTAprime plus. Each run shows a band at 12.5 kDa, which 
confirms successful isolation of MmMIF1 from total protein. Additional higher 
molecular weight bands can also be seen in lanes 2, 3, 4, 5 and although it is possible 
that those bands are contaminants, their molecular weights indicate that they are 
aggregates of MmMIF1 protein which were not visible after the samples were 
denatured thoroughly and for longer periods. Such a conclusion is drawn due to the 
observation that elutes of lower concentration in lanes 6 and 7 display clean bands at 
about 12.5 kDa. This is also seen after the Amicon-Ultra 15 filtration, where coomassie 
analysis of the filtered protein (fig. 4.3.B) shows that higher molecular weight bands 
are no longer present and after the last step of purification, where coomassie analysis 
(fig. 4.3.C) shows clean bands at 12.5 kDa (lanes 2 and 3) without any other additional 
bands indicating that pure MmMIF1 is obtained as observed on a 15% polyacrylamide 
gel. 
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Figure 4.3: MmMIF1 was successfully purified from E. coli BL21 Codon plus. 
Coomassie-stained polyacrylamide gels showing- A: Isolated MmMIF1 from total 
soluble protein after Ni2+ affinity chromatography on the ÄKTAprime plus. 1: Total 
soluble protein (control); 2-7: Elutes containing MmMIF1 from different runs. B: 
MmMIF1 after removal of salts and imidazole and after buffer exchange. 1: Mixed 
elutes after Ni2+ affinity chromatography (diluted 1:10). 2-5: Different dilutions of 
MmMIF1. C: MmMIF1 after reduced levels of residual endotoxin in the protein sample 
that were removed by anion exchange chromatography. 1: Pre- anion exchange control 
(diluted 1:20); 2, 3: Dilutions of purified MmMIF1. 
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At each stage, MmMIF1 was quantified using the Bicinchoninic acid assay (BCA) with a 
final concentration of 17 mg/mL after anion exchange chromatography. MmMIF1 was 
verified for presence of any residual endotoxin and was found to be 1.2 EU/mL.  These 
levels were acceptable for the subsequent bioassays since dilution of MmMIF1 to 
concentrations needed in the bioassay (0.01 μg/mL and 0.1 μg/mL) resulted in a final 
LPS concentration of ≤ 0.00007 ng/mL. The concentration of TsMIF1 was also 
measured and was found to be 30.7 mg/mL. Experiments for endotoxin detection in 
TsMIF1 using the LAL assay did not confirm the exact amount of endotoxin levels since 
measurements obtained even from a 1:300 diluted sample did not fit into the standard 
curve. However, from the absorbance values and endotoxin units (EU) obtained, it can 
be estimated that the endotoxin levels within the sample per mg was approximately 
4.1 ng/mL. The tautomerase activity of both TsMIF1 and MmMIF1 was tested after the 
final stage of purification (Fig. 4.4). It was found that TsMIF1 sustained higher 
tautomerase activity than MmMIF1.  
A 
 
     B 
 
Figure 4.4: TsMIF1 and MmMIF1 have tautomerase enzyme activity. Depletion of L-
dopa methyl ester in the presence or absence of TsMIF1 (A) or MmMIF1 (B) measured 
as an absorbance at OD475.  
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4.3 Validation of the sensitivity and specificity of the HEK-Blue™ hTLR4 
reporter cells 
The sensitivity and specificity of HEK-Blue™ hTLR4 cells was determined by detection 
of NFκB/ AP-1 activation and SEAP secretion into the media. HEK cell responses to 
different concentrations of LPS (a TLR4 ligand) were measured to make a standard 
curve showing their range of LPS sensitivity. Parallel experiments were also performed 
which included inhibitor polymyxin B sulfate (PMB) to confirm the specificity of the cell 
line for both activation and inhibition of TLR4 signalling. To allow normalisation of 
results between biological replicates the observed OD values were converted into a 
response ratio in Fig. 4.5.D and Fig. 4.5.F where 
𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑖𝑜 =
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
.  As seen in figure 4.5.C, 4.5.D and 
4.5.E, 4.5.F, the observed trend remains the same. All subsequent data obtained using 
this bioassay is represented as a response ratio.  
As seen from Fig. 4.5 and Fig. 4.6, NFκB/ AP-1 activation levels were found to increase 
with increasing concentration of LPS and decreased substantially upon co-treatment 
with inhibitor PMB. Results in fig 4.5 shows a steep increase in the activation of TLR4 in 
HEK-Blue™ hTLR4 cells when treated with 0.5 ng/mL LPS. Activation levels were found 
to peak at 1 ng/mL of LPS and do not increase significantly at higher concentrations. 
When cells were co-treated with 1 µg/mL PMB, LPS mediated activation of the SEAP 
reporter was abolished at concentrations ranging from 0.1 ng/mL to 10 ng/mL of LPS  
(Fig 4.6.A) with SEAP levels equivalent to the DPBS control. However, at higher 
concentrations of LPS (100ng/mL, 500ng/mL, 1000ng/mL) activation was inhibited but 
not abolished (Fig. 4.6.A). Based on these initial results the subsequent assessment of 
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MIF’s effects on this reporter assay were performed at the LPS concentrations ranging 
from 0.5 -10 ng/mL. 
 
A 
 
 
 B 
 
C 
 
 D 
 
E 
 
 F 
 
  
Figure 4.5: HEK-Blue™ hTLR4 cells respond to LPS in a dose dependant manner. A, B: 96-
well plates illustrating the two calorimetric methods: p-Nitrophenyl phosphate (pNPP) (A) 
and HEK-Blue™ Detection (B). HEK293 pNifty: 1-3: DPBS control, 4-6: 100 ng/mL TNFα, 7-9: 
LPS 100 ng/mL, 10-12: LPS 500 ng/mL. C, E:  HEK-Blue™ hTLR4 cells simulated with 
increasing concentrations of LPS (0.1 ng/mL - 1000 ng/mL) with or without inhibitor PMB. 
SEAP activity in the media was measured using pNPP solution at OD405 (C) or HEK-Blue™ 
Detection media at OD655 (E) respectively.  D, F: The response ratios of the LPS treated HEK-
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Blue™ cells as determined by the SEAP activity measured by pNPP solution (D) or HEK-Blue™ 
Detection (F). The values are represented as a response ratio where 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑖𝑜 =
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
. Values are mean for ± SEM, n=3.   
To show that activation of the HEK-Blue™ hTLR4 cells is due to the expression of a 
functional TLR4 receptor which is otherwise lacking in wild type (WT) HEK 293, HEK 
293 WT cells were transfected with the pNiFty2-SEAP reporter plasmid. Both HEK-
Blue™ hTLR4 and HEK293 pNifty2-SEAP cell populations were treated with LPS and 
responses were measured (Fig. 4.6). As seen in Fig. 4.6, HEK-Blue™ hTLR4 cells respond 
to LPS (Fig. 4.6.A) while HEK293 pNifty2-SEAP were unresponsive to LPS (Fig. 4.6.B).  To 
confirm the reporter construct was active in both cell lines they were also treated with 
a positive control 100 ng/mL TNF α  (Fig. 4.6.A and 4.6.B), which triggers NFκB and AP-
1 production via the IKK complex, via a TLR independent pathway. Both cell 
populations were shown to actively respond to TNFα stimulation with a response ratio 
of 2.5 and 5.4 for HEK-Blue™ hTLR4 cells (Fig. 4.6.A) and HEK293 pNifty2-SEAP (4.6.B) 
respectively. This indicates that the response to LPS is dependent on the expression of 
the TLR4 receptor and does not occur through other endogenous receptor. It also 
confirms that the reporter plasmid functions efficiently.   
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Figure 4.6: HEK-Blue™ hTLR4 cells respond to LPS only in the presence of a TLR4 receptor. A: 
HEK-Blue™ hTLR4 cells treated with different LPS concentrations (0.1 ng/mL - 1000 ng/mL) 
with (+) or without (-) 1 µg/mL of the inhibitor PMB. SEAP reporter activity was measured 
using pNPP solution at OD405. Values are mean for ± SEM, n=3. P≤ 0.05 (*), P≤ 0.01 (**), P≤ 
0.001 (***) for LPS vs LPS+PMB; P≤ 0.05 (●), P≤ 0.01 (●●), P≤ 0.001 (●●●) for untreated vs 
treated. B: HEK293 pNifty2-SEAP stimulated with 500 ng/mL and 1000 ng/mL of LPS or 100 
ng/mL TNF α. P≤ 0.001 (***) for TNF α vs LPS and TNF α vs untreated. Statistical analysis 
determined with One Way ANOVA and Bonferroni Post Hoc test for multiple comparisons. 
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4.4 Mus musculus MIF1 has no significant role in the activation of the 
TLR4 pathway 
After confirming the sensitivity and specificity of the HEK lines, cells were co- treated 
with Mus musculus MIF1 (MmMIF1) to determine if it influenced activation of the TLR4 
receptor. Cells were treated with a range of LPS concentrations (0.5 ng/mL, 1 ng/mL or 
10 ng/mL) and 0.01 µg/mL or 0.1 µg/mL of MmMIF1. Representative data of biological 
replicates is shown in Fig. 4.7. Additional experimental replicates are shown in Fig A.1 
in the appendix.  While there was a trend in some samples showing a reduction in TLR4 
activation after MmMIF1 treatment these differences were not statistically significant. 
MmMIF1 alone did not result in NFκB and AP-1 activation and co-treatment of cells 
with MmMIF1 and TNFα did not show any significant differences in the activity of the 
SEAP reporter (Fig. 4.7). This data indicates that MmMIF1 neither directly modulates 
LPS action via the TLR4 pathway nor TNFα action via the IKK complex.  
  
51 
 
  A 
 
B 
 
Figure 4.7: Co-administering MmMIF1 with LPS did not cause significant difference in 
activation of TLR4 pathway. A: HEK-Blue™ hTLR4 cells were co-treated with 0.01 µg/mL or 0.1 
µg/mL MmMIF1 and either 0.5 ng/mL or 1 ng/mL or 10 ng/mL LPS. The activation of the SEAP 
reporter is compared to cells treated with LPS alone. HEK-Blue™ hTLR4 cells treated with TNFα 
with or without MmMIF1 used as a positive control. Values are mean for ± SEM, n=3. P-value is 
non-significant (ns) for LPS vs LPS + MmMIF1. B: HEK293 pNifty2-SEAP subjected to 100 ng/mL 
TNFα with or without 0.01 µg/mL or 0.1 µg/mL of MmMIF1. Values are mean for ± SEM, n=3, 
P-value ns = non-significant, P > 0.05. Statistical analysis for both 4.7.A and 4.7.B determined 
with One Way ANOVA and Bonferroni Post Hoc test for multiple comparisons. 
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4.5 Trichinella spiralis MIF1 inhibits the  activation of the TLR4 receptor 
by LPS.  
To compare the activity of a pathogen derived MIF homolog to that of an endogenous 
mammalian MIF, cells were co-treated with a range of LPS concentrations (0.5 ng/mL, 
1 ng/mL, 10 ng/mL) and two concentrations of TsMIF1 (0.04 µg/mL, 0.4 µg/mL). 
Representative data of biological replicates is shown in Fig. 4.8. Additional 
experimental replicates are shown in Fig A.2 in the appendix.  Unlike MmMIF1 it was 
observed that treatment with both 0.04 µg/mL, 0.4 µg/mL of TsMIF1 lowered 
activation of the SEAP reporter relative to the cells treated with LPS alone. This 
inhibition was observed across all three LPS concentrations. However, inhibition levels 
were not at the same level for all three LPS concentrations and TsMIF1 appears to 
have the highest inhibitory activity when administered at lower concentrations to cells 
treated with 0.5-10 ng/mL LPS. This observation may be partially explained by the 
TsMIF1 only controls where the higher concentration of TsMIF1 also show activation of 
the SEAP reporter indicating there may be residual LPS contamination with in the 
recombinant protein preparations. When cells were co-treated with TsMIF1 and 100 
ng/mL TNFα, there was no significant difference in activity of the SEAP in comparison 
to responses with TNFα alone in either the HEK-Blue™ hTLR4 cells (Fig. 4.8.A) or 
HEK293 WT (Fig. 4.8.B). Thus, it is tempting to speculate that the suppressive action of 
TsMIF1 is through pathway components specific to TLR4 receptor signalling rather than 
the common components shared with the TNF transduction pathway such as the IKK 
complex. 
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  A
 
 
B 
 
Figure 4.8: TsMIF1 inhibits the action of LPS in HEK-Blue™ hTLR4 cells. A: 0.04 µg/mL or 0.4 
µg/mL TsMIF1 co-administered with either 0.5 ng/mL or 1 ng/mL or 10 ng/mL LPS in HEK-
Blue™ hTLR4 cells and compared to cells treated with LPS alone. HEK-Blue™ hTLR4 cells treated 
with TNFα with or without TsMIF1 used as a positive control. Values are mean for ± SEM, n=3. 
P≤ 0.05 (*), P≤ 0.01 (**), P≤ 0.001 (***) for LPS vs LPS+ TsMIF1. B: HEK293 pNifty2-SEAP 
subjected to treatment with 100 ng/mL TNFα alone with or without 0.04 µg/mL, 0.4 µg/mL 
TsMIF1. Values are mean for ± SEM, n=3, p- value non- significant (ns) for TNFα vs TNFα + 
TsMIF1. Statistical analysis for both 4.9.A and 4.9.B determined with One Way ANOVA and 
Bonferroni Post Hoc test for multiple comparisons. 
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5.0 Discussion 
In order to investigate the potential immunomodulatory properties of MIF1 in the 
activation of TLR4, a primary aim of this project was to clone, express and purify 
enzymatically active recombinant protein Mus musculus MIF1 using the pET29b 
bacterial expression vector. The effects of this recombinant were then tested in a TLR4 
activation assay using HEK-Blue™ hTLR4 cells.  In addition to testing the activities of 
MmMIF1 in the TLR4 bioassay, the effects of a parasite derived MIF1 homologue, 
Trichinella spiralis MIF1 was also assessed.  
5.1 Cloning, Expression and Purification of  enzymatic ally active MmMIF1 
from bacteria  
Murine MIF1 was successfully cloned into the bacterial expression vector pET29b (Fig. 
4.1.A) and incorporated into BL21 Codon plus E. coli (Fig. 4.1.B). The DNA gel 
electrophoresis of gene and plasmid specific diagnostic PCR products and sequencing 
(Fig. 4.1.C) confirmed the presence of the MmMIF1 cDNA and it’s orientation within 
the expression plasmid. Using IPTG as the protein induction stimulus, soluble MmMIF1 
was produced (Fig. 4.2). It was also confirmed by Western blot using a His-antibody 
(Fig. 4.3.D) that the MIF1 protein had an intact His-tag. Overnight express media was 
also used for protein induction, however, it did not induce detectable protein in the 
soluble fraction. This may be due to inadequate oxygenation/aeration as the supply of 
oxygen is limited after dense growth of the culture (Studier, 2005). Temperature might 
be another factor and optimisation by reducing the temperature of incubation to 
lower temperature such as 25oC - 30oC might improve the yield of soluble protein 
(Novagen). A number of studies suggest that the availability of oxygen and amino acids 
can dramatically influence the outcome of recombinant protein biosynthesis (Carnicer 
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et al., 2012, Blommel et al., 2007, Rosano and Ceccarelli, 2014). Although IPTG is a 
synthetic structural analogue of allolactose and is sometimes toxic when used in 
excessive amounts, the relatively low concentration used in this study (50 µM) may 
have been adequate for the induction of reasonable amounts of protein but was not so 
high that it results in the entire recombinant product being sequestered in inclusion 
bodies.  
Thus, the soluble fractions were successfully used to obtain purified MmMIF1 (Fig. 4.3) 
with a final concentration of 17 mg/mL. The purified protein was also free from 
residual endotoxin as determined by LAL assay with relevance to the physiological 
concentrations at which the MmMIF1 was diluted to in the TLR4 bioassay. This was 
further confirmed in the bioassays where MmMIF1 on its own did not trigger NFκB and 
AP-1 activation in HEK-Blue™ hTLR4 cells above basal levels (Fig. 4.7). Since it was 
established from dose-dependent experiments (Fig. 4.5 and Fig. 4.6.A) that HEK-Blue™ 
hTLR4 cells are responsive to LPS, the presence of any residual endotoxin in MmMIF1 
should have been observable in the results. This indicates that MmMIF1 is endotoxin 
free and also that by itself it does not initiate TLR4 activation. MmMIF1 also showed 
tautomerase activity between 0-135 seconds of the reaction (Fig. 4.4.B). However, the 
depletion in the substrate was much higher for TsMIF1 than MmMIF1. This is due to 
the difference in the activity across species (Fig. 4.4) which has been shown in a study 
by Tan et al., 2001. They demonstrated that TsMIF1 had 6- fold higher specificity and 
tautomerase activity towards L- dopachrome methyl ester than mammalian MIFs. It 
may also be due to the effect of the anion exchange chromatography column because 
it was observed that tautomerase activity of MmMIF1 before this procedure was 
higher (data not shown). It is possible that the cellulose based column matrix had 
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unexpected effects on the enzymatic activities of MIF and alternative matrix materials 
like polystyrene/divinyl benzene based columns such as Mini Q from GE Healthcare 
might help ensure that the protein remains stable during the polishing step of the 
purification. 
Similarly, TsMIF1 was also quantified with a final concentration of 30.7 mg/mL. The 
amount of residual endotoxin was not clearly established for TsMIF1 which may lead 
to the possibility that the endotoxin levels were high enough to interfere within the 
bioassay at higher TsMIF1 working concentration. This is observed in Fig. 4.8.A where 
HEK-Blue™ hTLR4 cells treated with 0.4 μg/mL of TsMIF1 alone resulted in higher 
activation of the SEAP reporter when compared to cells treated with either 0.04 μg/mL 
of TsMIF1 or DPBS. If TsMIF1 was inherently capable of activating TLR4 we would 
predict it would also act at lower concentrations such as 0.04 μg/mL concentration so 
the most likely explanation is that residual endotoxin within the recombinant protein 
caused base line activation observed in the assay and may have obscured inhibitory 
activities seen at the lower concentrations. To confirm this possibility the recombinant 
protein requires further purification via anion exchange chromatography and the TLR4 
bioassays repeated. 
5.2 Sensitivity and Specificity of the HEK-Blue™ hTLR4 Bioassay  
Initial experiments using the HEK-Blue™ hTLR4 cells and WT HEK293 pNifty2-SEAP 
control cells isolated during this study showed that cell lines and the SEAP reporter 
used in this study specifically respond LPS treatment (Fig. 4.5 and Fig. 4.6). Cells lacking 
the TLR4 receptor showed minimal SEAP activity and control experiments treating cells 
with TNFα which has an intact receptor and signalling complex in WT HEK cells 
confirmed that SEAP responsiveness to signalling via the IKK complex. Although WT 
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HEK293 cells cannot express surface TLR4, MD-2 and CD14 which are essential for 
successful TLR4 activation with LPS, it contains all downstream proteins common to 
the TNFR1 pathway which can be activated in TLR4 independent manner. The 
sensitivity of the HEK-Blue™ hTLR4 cells was also assessed using HEK-Blue™ Detection 
media and p-Nitrophenyl phosphate (pNPP) assays (Fig. 4.5) which confirmed that both 
the methods have similar trends and are interchangeable in terms of both sensitivity 
and specificity. Within these assays the sensitivity range of the assay was also 
established with concentrations of LPS at which SEAP activity were within a linear 
concentration range spanning 0.1-10ng/mL. These optimised assay conditions for the 
reporter cells were then used to assess the effects of MmMIF1 and TsMIF1 treatment 
on TLR4 signalling with LPS simulation concentrations ranging from 0.5-10ng/mL. 
5.3 TsMIF1 inhibits activation of the HEK-Blue™ hTLR4 cells by LPS  unlike 
MmMIF1 
TsMIF1 was found to significantly inhibit activation that was stimulated and initiated 
by LPS (Fig. 4.8). It can be inferred that this effect of TsMIF1 was through the TLR4 
receptor specific signalling processes because there were no differences in the 
activation levels when it was co-administered with TNFα in both HEK-Blue™ hTLR4 cells 
and HEK293 pNifty2-SEAP. At a low concentration (0.04 μg/mL) TsMIF1 treatment on 
its own did not cause significant activation of the SEAP reporter. As discussed earlier, 
this is potentially due to residual endotoxin contamination within the recombinant 
protein. Therefore, we speculate that TsMIF1 may modulate the action of LPS through 
the TLR4 receptor at a point upstream of the IKK complex. As it was shown in Fig. 1.7, 
TGFβ activated Kinase 1 (TAK1) is the common point at which the two pathways 
intersect. Since TsMIF1 altered SEAP activation levels only when co-administered with 
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LPS and not with TNFα, the scope of signalling intermediates that TsMIF1 might affect 
would range from TLR4 receptor itself at the surface to TRAF6 which is the protein just 
upstream of TAK1  (Fig. 1.7). Identifying the intermediates may be achieved by 
analysing changes in the mRNA expression levels of these proteins within the pathway 
with or without MIF treatment using quantitative real-time PCR (qPCR). Detecting 
phosphorylated intermediates such as TAK1 by immunoblotting may provide insights 
into activated proteins in the pathway with or without MIF. MmMIF1 did not show any 
significant changes in the activation levels triggered either through the TLR4 pathway 
or the TNFR1 cascade. 
One additional complication of this study is that one of the putative MIF receptor 
complexes - CD74/CD44 is expressed at low levels in HEK cells which may mean they 
are less responsive via this pathway than relative to other cell types such as APCs. 
Previous studies have shown that mammalian MIFs trigger phosphorylation of ERK1 
and ERK2 via CD74/CD44 (Leng et al., 2003 Shi et al., 2006). However, other known 
MIF receptors such as Jab1 are expressed in HEK cells and the results found after 
treatment with TsMIF1 may indicate they play an important role in regulating TLR4 
signalling events. Increasing expression levels of the CD74/CD44 receptor complex in 
the HEK reporter cells either via transfection or transduction will allow the relative 
contribution of the different MIF receptors to the phenotype observed in this study to 
be specifically evaluated.  
It is also important to understand whether enzymatic activities of the recombinant 
MIFs (tautomerase and oxidoreductase) are linked to effects observed in this study. 
Use of specific enzyme inhibitors such as: 4-iodo-6-phenylpyrimidine (4-IPP) that 
covalently modifies Proline 2 at the N-terminal and shown to inhibit internalisation of 
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MIF/CD74 (Varinelli et al., 2015); or p425, an allosteric inhibitor of MIF’s tautomerase 
activity that has been shown to inhibit MIF/CD74 interaction and modulate the pro-
inflammatory activities of MIF (Bai et al., 2012).  Another approach would be to 
generate mutant recombinant proteins lacking these enzyme active sites. These 
approaches will further our understanding on whether the tautomerase site of MIF is 
involved in the effects observed with NFκB and AP-1 activation. If the SEAP activity 
shows any changes upon this inhibition, measuring differential activation of proteins in 
the MAPK or the MIF/CD74 pathway will provide further insight about the exact 
mechanisms underlying MIF’s modulation of this pathway. 
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6.0 Concluding remarks 
To conclude, enzymatically active MmMIF1 and TsMIF1 were successfully cloned, 
expressed and purified for bioassays. Initial results indicate that TsMIF1 suppressed 
the LPS induced activation of the SEAP reporter while MmMIF1 did not seem to show 
any significant effects in this bioassay. Further characterisation and comparison of 
TsMIF1’s activities relative to mammalian MIFs is particularly important as it might 
help further our understanding of how this parasite evades host immune responses 
and could potentially be a starting point for the development of novel therapeutic 
agents for GI inflammation since it inhibits the activation of at least one inflammatory 
responses pathway that is important in a number of human pathological conditions.   
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Appendix 
  A 
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       C 
 
Figure A.1: Co-administering MmMIF1 with LPS did not cause significant difference in 
activation of TLR4 pathway. A, C: HEK-Blue™ hTLR4 cells were co-treated with 0.01 µg/mL 
or 0.1 µg/mL MmMIF1 and either 0.5 ng/mL or 1 ng/mL or 10 ng/mL LPS. The activation of 
the SEAP reporter is compared to cells treated with LPS alone. HEK-Blue™ hTLR4 cells 
treated with TNFα with or without MmMIF1 used as a positive control. Values are mean for 
± SEM, n=3. P-value is non-significant (ns) for LPS vs LPS + MmMIF1. B: HEK293 pNifty2-
SEAP subjected to 100 ng/mL TNFα with or without 0.01 µg/mL or 0.1 µg/mL of MmMIF1. 
Values are mean for ± SEM, n=3, P-value ns, non-significant, P > 0.05. Statistical analysis for 
both A.1.A and A.1.B determined with One Way ANOVA and Bonferroni Post Hoc test for 
multiple comparisons. 
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Figure A.2: TsMIF1 inhibits the action of LPS in HEK-Blue™ hTLR4 cells. A, C: 0.04 µg/mL or 
0.4 µg/mL TsMIF1 (A) or 0.4 µg/mL or 4 µg/mL (C) TsMIF1 co-administered with either 0.5 
ng/mL or 1 ng/mL or 10 ng/mL LPS in HEK-Blue™ hTLR4 cells and compared to cells treated 
with LPS alone. HEK-Blue™ hTLR4 cells treated with TNFα with or without TsMIF1 used as a 
positive control. Values are mean for ± SEM, n=3. P≤ 0.05 (*), P≤ 0.01 (**), P≤ 0.001 (***),P ≥ 
0.05 (ns) for LPS vs LPS+ TsMIF1. B, D: HEK293 pNifty2-SEAP subjected to treatment with 100 
ng/mL TNFα alone with or without 0.04 µg/mL, 0.4 µg/mL (A); 0.4 µg/mL, 4 µg/mL (C) TsMIF1. 
Values are mean for ± SEM, n=3, P- value non- significant (ns) for TNFα vs TNFα + TsMIF1. 
Statistical analysis determined with One Way ANOVA and Bonferroni Post Hoc test for 
multiple comparisons. 
 
